The RhoA G17V mutation, associated with loss of GTPase function, is recurrently found in up to 60-70% of AITL cases, and is currently considered a diagnostic biomarker for nMTCL-TFH-phenotype (24, 25, 50–52). Here, RHOA is linked to angioimmunoblastic T-cell lymphoma.